Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has a beta value of 0.48 and has seen 1.03 million shares traded in the last trading session. The company, currently valued at $43.45M, closed the last trade at $0.62 per share which meant it gained $0.05 on the day or 9.35% during that session. The BCLI stock price is -438.71% off its 52-week high price of $3.34 and 79.03% above the 52-week low of $0.13. The 3-month trading volume is 988.61K shares.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Sporting 9.35% in the green in last session, the stock has traded in the green over the last five days, when the BCLI stock price touched $0.62 or saw a rise of 2.12%. Year-to-date, Brainstorm Cell Therapeutics, Inc. shares have moved 127.11%, while the 5-day performance has seen it change 23.98%. Over the past 30 days, the shares of Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) have changed 14.79%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Figures show that Brainstorm Cell Therapeutics, Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 244.44% over the past 6 months, with this year growth rate of 45.10%, compared to 14.90% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.57% over the past 5 years.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
